| Id |
Subject |
Object |
Predicate |
Lexical cue |
| SS1_22788263_2_0 |
229-269 |
expanded |
denotes |
Attention-deficit hyperactivity disorder |
| SS2_22788263_2_0 |
271-275 |
abbr |
denotes |
ADHD |
| SS1_22788263_6_0 |
706-733 |
expanded |
denotes |
cost-effectiveness analysis |
| SS2_22788263_6_0 |
735-738 |
abbr |
denotes |
CEA |
| SS1_22788263_6_1 |
767-794 |
expanded |
denotes |
guanfacine extended release |
| SS2_22788263_6_1 |
796-799 |
abbr |
denotes |
GXR |
| SS1_22788263_10_0 |
1254-1289 |
expanded |
denotes |
Clinical Global Impression-Severity |
| SS2_22788263_10_0 |
1291-1296 |
abbr |
denotes |
CGI-S |
| SS1_22788263_15_0 |
2121-2155 |
expanded |
denotes |
probabilistic sensitivity analysis |
| SS2_22788263_15_0 |
2157-2160 |
abbr |
denotes |
PSA |
| SS1_22788263_18_0 |
2599-2635 |
expanded |
denotes |
incremental cost-effectiveness ratio |
| SS2_22788263_18_0 |
2637-2641 |
abbr |
denotes |
ICER |
| AE1_22788263_10_0 |
SS1_22788263_10_0 |
SS2_22788263_10_0 |
abbreviatedTo |
Clinical Global Impression-Severity,CGI-S |
| AE1_22788263_15_0 |
SS1_22788263_15_0 |
SS2_22788263_15_0 |
abbreviatedTo |
probabilistic sensitivity analysis,PSA |
| AE1_22788263_18_0 |
SS1_22788263_18_0 |
SS2_22788263_18_0 |
abbreviatedTo |
incremental cost-effectiveness ratio,ICER |
| AE1_22788263_2_0 |
SS1_22788263_2_0 |
SS2_22788263_2_0 |
abbreviatedTo |
Attention-deficit hyperactivity disorder,ADHD |
| AE1_22788263_6_0 |
SS1_22788263_6_0 |
SS2_22788263_6_0 |
abbreviatedTo |
cost-effectiveness analysis,CEA |
| AE1_22788263_6_1 |
SS1_22788263_6_1 |
SS2_22788263_6_1 |
abbreviatedTo |
guanfacine extended release,GXR |
